Fibrinogen

Carcinogenic and mutagenic risk assessments^{15 (link),60 (link)–63 (link),67 (link)–69 (link)} induced by inhalation of PM2.5-bound enriched with selected nitro-PAHs (1-NPYR, 2-NPYR, 2-NFLT, 3-NFLT, 2-NBA, and 3-NBA) and PAHs (PYR, FLT, BaP, and BaA) were estimated in the bus station and coastal site samples according to calculations done by Wang et al.^{60 (link)}, Nascimento et al.^{61 (link)}, and Schneider et al.^{67 (link)} PAH and PAH derivatives risk assessment is done in terms of BaP toxicity, which is well established^{67 (link)–73 (link)}. The daily inhalation levels (E_I) were calculated as: $$E_I=Ba{P}_{eq}\times IR=(\sum C_i\times TE{F}_i)\times IR$$ where E_I (ng person⁻¹ day⁻¹) is the daily inhalation exposure, IR (m³ d⁻¹) is the inhalation rate (m³ d⁻¹), BaP_eq is the equivalent of benzo[a]pyrene (BaP_eq = Σ C_i × TEF_i) (in ng m⁻³), C_i is the PM2.5 concentration level for a target compound i, and TEF_i is the toxic equivalent factor of the compound i. TEF values were considered those from Tomaz et al.^{15 (link)}, Nisbet and LaGoy^{69 (link)}, OEHHA⁷² , Durant et al.^{73 (link)}, and references therein. E_I in terms of mutagenicity was calculated using equation (1), just replacing the TEF data by the mutagenic potency factors (MEFs) data, published by Durant et al.^{73 (link)}. Individual TEFs and MEFs values and other data used in this study are described in SI, Table S4.
The incremental lifetime cancer risk (ILCR) was used to assess the inhalation risk for the population in the Greater Salvador, where the bus station and the coastal site are located. ILCR is calculated as: $$ILCR=(E_I\times SF\times E_D\times cf\times EF)/(AT\times BW)$$ where SF is the cancer slope factor of BaP, which was 3.14 (mg kg⁻¹ d⁻¹)⁻¹ for inhalation exposure^{60 (link)}, EF (day year⁻¹) represents the exposure frequency (365 days year⁻¹), E_D (year) represents exposure duration to air particles (year), cf is a conversion factor (1 × 10⁻⁶), AT (days) means the lifespan of carcinogens in 70 years (70 × 365 = 25,550 days)^{70 ,72} , and BW (kg) is the body weight of a subject in a target population⁷¹ .
The risk assessment was performed considering four different target groups in the population: adults (>21 years), adolescents (11–16 years), children (1–11 years), and infants (<1 year). The IR for adults, adolescents, children, and infants were 16.4, 21.9, 13.3, 6.8 m³ day⁻¹, respectively. The BW was considered 80 kg for adults, 56.8 kg for adolescents, 26.5 kg for children and 6.8 kg for infants⁷⁰ .

For Fig. 4d, e and the credible set analysis we used autosomal markers only, and filtered markers in each data source such that MAF > 0.001 (defined in the GWAS population), and Info score > 0.3 in the UK Biobank imputed data. There were 16,443,622 such markers in UK Biobank imputed data, 703,946 in the UK Biobank genotyped data, and 2,546,872 in GIANT.
For a given phenotype, the 95% credible set in a region of association is the smallest set of markers that together have 95% posterior probability of containing the marker causally associated with the phenotype. We found credible sets for standing height using the method described previously^{33 (link)} and summarize the results in Extended Data Fig. 6. It is important to note that this approach is based on a model in which there is exactly one causal marker in the region and genotypes for that marker are available in the data. Our results should therefore be considered as indicative of a more detailed analysis where, for example, the regions are first analysed to distinguish independent association signals.
In our analysis, we first defined a set of 575 non-overlapping regions associated with standing height using a procedure based on that used previously^{15 (link)} (see Supplementary Information). For each study, we carried out two separate analyses to find credible sets in these regions: (A) using all the markers in each study (768,502 in UK Biobank imputed data; 106,263 in GIANT); and (B) using only those markers in both studies (105,421).
For each marker in each study, we computed a Bayes factor in favour of association with standing height using the effect sizes and standard errors, and 0.2² as the prior^{33 (link)} on the variance of the effect sizes. To ensure the effect sizes were on the same scale in both studies we scaled UK Biobank effect sizes and standard errors by the standard deviation of the residuals of the measured phenotype (standing height) after regressing out the covariates used in the GWAS. We then confirmed that the effect size estimates for overlapping markers were comparable between the two studies.
If there is exactly one causal marker in the region and genotypes for that marker are available in the data, then the posterior probability that a marker i drives the association signal in the region r is given by: $${\pi }_{ir}=\frac{{\mathrm{BF}}_{ir}}{{\mathrm{\Sigma }}_k{\mathrm{BF}}_{kr}}$$ where BF_kr is the Bayes factor for marker i in the r region^{33 (link)}. The 95% credible set for a region is found by going down the list of markers ordered from highest to lowest posterior probability and stopping when the cumulative posterior reaches 0.95.
We assessed the sensitivity of our results to the choice of prior by conducting the same analyses using a much smaller prior (0.02²) and much larger prior (20²). We found that overall the choice of prior had little effect on the results. Specifically for values we report in the main text, the median credible set sizes were unaffected in all analyses. For the larger prior, the number of single-marker credible sets was unaffected except for analysis B in UK Biobank (from 123 to 122), and the median proportion of markers in the credible set was unaffected in all analyses. For the smaller prior, the number of single-marker credible sets only changed for analysis A, going from 78 to 75 in GIANT, and 85 to 86 in UK Biobank, and the median proportion of markers in the credible set increased slightly in all analyses (maximum increase from 0.047 to 0.051).

Detailed baseline and clinicopathological information, including sex, age, tumor location, tumor size, pathological type, differentiation, lymph node metastasis, and TNM stage of the patients with pancreatic diseases and HC, were obtained from the medical records of the inpatients or outpatients. The preoperative hematological parameters and liver function tests included neutrophils (× 10⁹/L), lymphocytes (× 10⁹/L), monocytes (× 10⁹/L), platelets (× 10⁹/L), plasma fibrinogens (g/L), serum albumins (g/L), prealbumin (mg/L), and CA199 (U/L) within seven days before surgery (average 2—7 days) were gathered from the medical records. TNM staging was performed using the 8th edition of the AJCC Cancer Staging Manual for Pancreatic Cancer.

FAR, FPR, NLR, PLR, MLR, and FLR were defined as the plasma fibrinogen value divided by the serum albumin value, plasma fibrinogen value divided by the serum prealbumin value, neutrophil count divided by the lymphocyte count, platelet count divided by the lymphocyte count, monocyte count divided by the lymphocyte count, and plasma fibrinogen value divided by the lymphocyte count, respectively. PNI was defined as serum albumin value + 5 × lymphocyte count.